Immune Pathways Help Identify Patients with Cancer and HIV Most Likely to Experience Reservoir Decay with Anti-PD1 Therapy By Ogkologos - March 9, 2026 152 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from multiomic profiling in the CITN-12 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Joins WHO Global Clinical Trials Forum to Strengthen Global Oncology Research Ecosystems EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses Over Ruxolitinib in Patients with JAK Inhibitor-Naïve Myelofibrosis MOST POPULAR An Increase in Healthcare Costs Associated with the Use of Multigene... February 14, 2024 Study Tackles Key Questions about Liver Transplants for People with Liver... August 24, 2022 Could A Form of Cell Death Enhance Cancer Immunotherapy? July 29, 2019 EMA Recommends Extension of Therapeutic Indications for Atezolizumab May 24, 2022 Load more HOT NEWS Cancer Research UK spin-out goes public, ready to invest more in... What Happens If More People Get Screened for Cancer? Neoadjuvant Nivolumab Plus Ipilimumab Shows Trend Towards Long-Term Clinical Benefit versus... Combination of Azacitidine and Venetoclax in Previously Untreated AML
